Erythropoietin beyond red blood cells: Systemic and oncological functions (Review).
Erythropoietin has roles beyond red blood cell production, but many of its potential applications are still under investigation and not yet clinically validated.
Where it sits
this study against the rest of the erythropoietin (epo) corpusSummary and findings
This review discusses erythropoietin (Epo) as a regulator of hematopoiesis and its potential systemic functions beyond red blood cell production. It highlights Epo's tissue-protective effects and its implications in cancer-related anemia and tumor biology. The review emphasizes that many applications of Epo derivatives are still in preclinical or early clinical stages.
Abstract
Erythropoietin (Epo) is widely recognized as the primary regulator of haematopoiesis, managing red blood cell production via erythropoietin receptor (EPOR) expressed on erythroid progenitors. Beyond erythropoiesis, Epo functions as a pleiotropic cytokine, exhibiting marked tissue‑protective effects across various non‑haematopoietic systems, including neuroprotection, cardioprotection, anti‑inflammatory effects and promotion of angiogenesis. Clinically, recombinant Epo is widely used to alleviate cancer‑related anaemia and improve haemoglobin levels. However, the presence of EPOR in malignant tissues may directly influence tumour progression or angiogenesis. The aim of the present review is to summarize current knowledge on Epo signalling across multiple organ systems, to discuss the possible applications of Epo derivatives, and to refer to emerging evidence suggesting that Epo may affect tumour biology and modulate the efficacy of chemotherapy. The review provides a comprehensive overview of current and emerging therapeutic concepts involving Epo derivatives, while emphasizing that most non‑haematopoietic applications remain under preclinical or early clinical investigation.
Background
This review addresses the multifaceted roles of erythropoietin (Epo) beyond its established function in red blood cell production. Prior knowledge indicates that Epo primarily regulates haematopoiesis through its receptor on erythroid progenitors. Understanding Epo's broader implications is crucial as it may influence various physiological processes and disease states.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
The review suggests that while Epo has potential therapeutic applications in various non-haematopoietic contexts, the evidence remains largely preclinical or in early clinical stages. The implications for clinical practice are limited due to the lack of robust human data supporting these additional roles of Epo.
Key findings
- Not reported in abstract.
Limitations
- Most applications remain under preclinical or early clinical investigation.
- Not a primary research study; it is a review.